<DOC>
	<DOCNO>NCT00363090</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , work different way stop growth cancer cell , either kill cell stop grow . Giving alemtuzumab together combination chemotherapy may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose alemtuzumab give together combination chemotherapy see well work treat patient newly diagnose aggressive stage II , stage III , stage IV T-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Alemtuzumab Combination Chemotherapy Treating Patients With Newly Diagnosed Stage II , Stage III , Stage IV T-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Establish safety dose-limiting toxicity alemtuzumab combination cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone ( CHOP ) chemotherapy patient newly diagnose , stage II-IV aggressive peripheral T-cell non-Hodgkin 's lymphoma . - Measure pharmacokinetics alemtuzumab use different subcutaneous dos schedule determine dose high achievable drug level acceptable toxicity worthy investigation . Secondary - Determine efficacy alemtuzumab combination CHOP chemotherapy use escalate dos 2 different drug schedule , define overall response rate , progression-free survival , overall survival . - Measure effect regimen T-cell reconstitution cytomegalovirus reactivation . OUTLINE : This multicenter , phase I , dose-escalation study alemtuzumab follow open-label , phase II study . - Phase I : Patients receive CHOP chemotherapy comprise cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV day 1 oral prednisone day 1-5 . Patients also receive alemtuzumab subcutaneously ( SC ) day 1 OR day 1 , 8 , 15 . Treatment repeat every 3 week 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos alemtuzumab maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive CHOP chemotherapy alemtuzumab ( MTD determine phase I ) phase I ( effective regimen ) . Patients undergo blood collection baseline , periodically study treatment , completion study treatment pharmacokinetics correlative study . Samples examine presence cytomegalovirus antigen flow cytometry B- T-cell quantification . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 84 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive peripheral Tcell nonHodgkin 's lymphoma ( NHL ) , include follow nodal extranodal subtypes : Nodal : Angioimmunoblastic lymphadenopathy ALK 1negative anaplastic large cell NHL Peripheral Tcell lymphoma otherwise specify Extranodal : Hepatosplenic NHL Enteropathyassociated NHL Panniculitic NHL Stage IIIV disease Newly diagnose , CD52+ disease Measurable evaluable disease No known CNS involvement lymphoma No nasal natural killer Tcell NHL PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 4 month Absolute neutrophil count ≥ 1,000/mm³* Platelet count ≥ 75,000/mm³* Hemoglobin ≥ 8.5 g/dL* Bilirubin &lt; 2.0 mg/dL Alkaline phosphatase ≤ 2 time upper limit normal ( ULN ) AST ALT &lt; 2 time ULN Creatinine &lt; 1.5 mg/dL* Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity study drug No serious illness would preclude compliance study requirement No known HIV positivity No preexisting immunodeficiency ( e.g. , postorgan transplant ) No malignancy within past 5 year except cervical carcinoma situ nonmelanoma skin cancer NOTE : *Unless directly attributable NHL PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy Up 7 day prednisone precede initiation chemotherapy allow No concurrent chemotherapy , radiotherapy , immunotherapy No concurrent corticosteroid except dexamethasone use antiemetic brief period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
</DOC>